APA (7th ed.) Citation

Maetzel, A., Krahn, M., & Naglie, G. (2003). The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arthritis and rheumatism, 49(3), 283-292. https://doi.org/10.1002/art.11121

Chicago Style (17th ed.) Citation

Maetzel, Andreas, Murray Krahn, and Gary Naglie. "The Cost Effectiveness of Rofecoxib and Celecoxib in Patients with Osteoarthritis or Rheumatoid Arthritis." Arthritis and Rheumatism 49, no. 3 (2003): 283-292. https://doi.org/10.1002/art.11121.

MLA (9th ed.) Citation

Maetzel, Andreas, et al. "The Cost Effectiveness of Rofecoxib and Celecoxib in Patients with Osteoarthritis or Rheumatoid Arthritis." Arthritis and Rheumatism, vol. 49, no. 3, 2003, pp. 283-292, https://doi.org/10.1002/art.11121.